Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced that it will report financial results for the three and twelve months ended December 31, 2019 after the close of the U.S. financial markets on Thursday, March 5, 2020.
February 27, 2020
· 2 min read